Improvement in Hematopoiesis after Iron Chelation Therapy with Deferasirox in Patients with Aplastic Anemia

By  

Acta Haematologica, Vol. 129, Iss. 2, 2012-11 ,pp. : 72-77

Karger

Access to resources Recommend Favorite

Two-Year Analysis of Efficacy and Safety of Deferasirox Treatment for Transfusional Iron Overload in Sickle Cell Anemia Patients

By  

Acta Haematologica, Vol. 128, Iss. 2, 2012-06 ,pp. : 113-118

Karger

Access to resources Recommend Favorite

Oral Iron Chelator Deferasirox in the Treatment of Secondary Hemochromatosis following Bone Marrow Transplantation in a Patient with Severe Aplastic Anemia

By  

Acta Haematologica, Vol. 125, Iss. 4, 2011-01 ,pp. : 219-221

Karger

Access to resources Recommend Favorite

Iron Chelation in the Treatment of Cancer: A New Role for Deferasirox?

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 53, Iss. 9, 2013-09 ,pp. : 885-891

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom

By Karnon J.   Tolley K.   Oyee J.   Jewitt K.   Ossa D.   Akehurst R.  

Current Medical Research and Opinion, Vol. 24, Iss. 6, 2008-06 ,pp. : 1609-1621

Informa Healthcare

Access to resources Recommend Favorite